Which has better earnings & valuation, LIVN or IRMD?

iRadimed has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.12 -$242.47M $3.38 23.30 iRadimed $83.81M 13.41 $22.48M $1.79 49.08

Is LIVN or IRMD more profitable?

iRadimed has a net margin of 26.70% compared to LivaNova's net margin of 12.82%. iRadimed's return on equity of 23.45% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% iRadimed 26.70% 23.45% 20.36%

Does the media refer more to LIVN or IRMD?

In the previous week, LivaNova had 1 more articles in the media than iRadimed. MarketBeat recorded 4 mentions for LivaNova and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.18 beat LivaNova's score of 0.14 indicating that iRadimed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iRadimed 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, IRMD or ITGR?

Integer has higher revenue and earnings than iRadimed. Integer is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.41 $22.48M $1.79 49.08 Integer $1.84B 2.31 $102.81M $3.66 34.21

Is IRMD or ITGR more profitable?

iRadimed has a net margin of 26.70% compared to Integer's net margin of 6.97%. iRadimed's return on equity of 23.45% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% Integer 6.97% 12.79% 6.48%

Does the media favor IRMD or ITGR?

In the previous week, Integer had 5 more articles in the media than iRadimed. MarketBeat recorded 8 mentions for Integer and 3 mentions for iRadimed. Integer's average media sentiment score of 1.42 beat iRadimed's score of 1.18 indicating that Integer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integer 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRMD or IRTC?

In the previous week, iRhythm Technologies had 3 more articles in the media than iRadimed. MarketBeat recorded 6 mentions for iRhythm Technologies and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.18 beat iRhythm Technologies' score of 0.28 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, IRMD or PLSE?

iRadimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.41 $22.48M $1.79 49.08 Pulse Biosciences $1.19M 2,944.78 -$72.78M -$1.18 N/A

Is IRMD or PLSE more profitable?

iRadimed has a net margin of 26.70% compared to Pulse Biosciences' net margin of -6,755.78%. iRadimed's return on equity of 23.45% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% Pulse Biosciences -6,755.78% -94.42% -79.96%

Does the media refer more to IRMD or PLSE?

In the previous week, Pulse Biosciences had 5 more articles in the media than iRadimed. MarketBeat recorded 8 mentions for Pulse Biosciences and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.18 beat Pulse Biosciences' score of 0.76 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, IRMD or TMDX?

TransMedics Group has higher revenue and earnings than iRadimed. TransMedics Group is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.41 $22.48M $1.79 49.08 TransMedics Group $605.49M 5.41 $190.29M $3.89 24.36

Does the media prefer IRMD or TMDX?

In the previous week, TransMedics Group had 9 more articles in the media than iRadimed. MarketBeat recorded 12 mentions for TransMedics Group and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.18 beat TransMedics Group's score of 0.82 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

iRadimed (IRMD) Competitors

$87.85 +1.17 (+1.35%)

As of 08/21/2026 04:00 PM Eastern

Compare

IRMD vs. LIVN, ITGR, IRTC, PLSE, and TMDX

Should you buy iRadimed stock or one of its competitors? iRadimed's main competitors and comparable companies include LivaNova (LIVN), Integer (ITGR), iRhythm Technologies (IRTC), Pulse Biosciences (PLSE), and TransMedics Group (TMDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does iRadimed compare to LivaNova?

LivaNova (NASDAQ:LIVN) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

In the previous week, LivaNova had 1 more articles in the media than iRadimed. MarketBeat recorded 4 mentions for LivaNova and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.18 beat LivaNova's score of 0.14 indicating that iRadimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRadimed	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.6% of LivaNova shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 34.6% of iRadimed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LivaNova presently has a consensus price target of $83.50, indicating a potential upside of 6.05%. iRadimed has a consensus price target of $120.00, indicating a potential upside of 36.60%. Given iRadimed's stronger consensus rating and higher possible upside, analysts plainly believe iRadimed is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80

LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, iRadimed has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

iRadimed has a net margin of 26.70% compared to LivaNova's net margin of 12.82%. iRadimed's return on equity of 23.45% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
iRadimed	26.70%	23.45%	20.36%

iRadimed has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.12	-$242.47M	$3.38	23.30
iRadimed	$83.81M	13.41	$22.48M	$1.79	49.08

Summary

iRadimed beats LivaNova on 12 of the 17 factors compared between the two stocks.

How does iRadimed compare to Integer?

iRadimed (NASDAQ:IRMD) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

iRadimed presently has a consensus target price of $120.00, indicating a potential upside of 36.60%. Integer has a consensus target price of $109.86, indicating a potential downside of 12.27%. Given iRadimed's stronger consensus rating and higher probable upside, research analysts plainly believe iRadimed is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

iRadimed has a net margin of 26.70% compared to Integer's net margin of 6.97%. iRadimed's return on equity of 23.45% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
Integer	6.97%	12.79%	6.48%

iRadimed has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Integer has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 34.6% of iRadimed shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Integer has higher revenue and earnings than iRadimed. Integer is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.41	$22.48M	$1.79	49.08
Integer	$1.84B	2.31	$102.81M	$3.66	34.21

In the previous week, Integer had 5 more articles in the media than iRadimed. MarketBeat recorded 8 mentions for Integer and 3 mentions for iRadimed. Integer's average media sentiment score of 1.42 beat iRadimed's score of 1.18 indicating that Integer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integer	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iRadimed beats Integer on 11 of the 17 factors compared between the two stocks.

How does iRadimed compare to iRhythm Technologies?

iRadimed (NASDAQ:IRMD) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

iRadimed has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

In the previous week, iRhythm Technologies had 3 more articles in the media than iRadimed. MarketBeat recorded 6 mentions for iRhythm Technologies and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.18 beat iRhythm Technologies' score of 0.28 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

iRadimed has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.41	$22.48M	$1.79	49.08
iRhythm Technologies	$747.14M	5.67	-$44.55M	-$0.43	N/A

iRadimed currently has a consensus price target of $120.00, indicating a potential upside of 36.60%. iRhythm Technologies has a consensus price target of $179.93, indicating a potential upside of 40.00%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

iRadimed has a net margin of 26.70% compared to iRhythm Technologies' net margin of -1.69%. iRadimed's return on equity of 23.45% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
iRhythm Technologies	-1.69%	10.11%	1.53%

92.3% of iRadimed shares are held by institutional investors. 34.6% of iRadimed shares are held by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

iRadimed beats iRhythm Technologies on 10 of the 17 factors compared between the two stocks.

How does iRadimed compare to Pulse Biosciences?

iRadimed (NASDAQ:IRMD) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

iRadimed has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

iRadimed has a net margin of 26.70% compared to Pulse Biosciences' net margin of -6,755.78%. iRadimed's return on equity of 23.45% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

92.3% of iRadimed shares are held by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are held by institutional investors. 34.6% of iRadimed shares are held by insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Pulse Biosciences had 5 more articles in the media than iRadimed. MarketBeat recorded 8 mentions for Pulse Biosciences and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.18 beat Pulse Biosciences' score of 0.76 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 36.60%. Pulse Biosciences has a consensus price target of $45.25, indicating a potential downside of 10.25%. Given iRadimed's stronger consensus rating and higher possible upside, equities analysts clearly believe iRadimed is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

iRadimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.41	$22.48M	$1.79	49.08
Pulse Biosciences	$1.19M	2,944.78	-$72.78M	-$1.18	N/A

Summary

iRadimed beats Pulse Biosciences on 12 of the 17 factors compared between the two stocks.

How does iRadimed compare to TransMedics Group?

iRadimed (NASDAQ:IRMD) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

iRadimed has a net margin of 26.70% compared to TransMedics Group's net margin of 22.69%. iRadimed's return on equity of 23.45% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
TransMedics Group	22.69%	15.88%	5.95%

iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 36.60%. TransMedics Group has a consensus price target of $124.18, indicating a potential upside of 31.03%. Given iRadimed's stronger consensus rating and higher probable upside, analysts clearly believe iRadimed is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, TransMedics Group had 9 more articles in the media than iRadimed. MarketBeat recorded 12 mentions for TransMedics Group and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.18 beat TransMedics Group's score of 0.82 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has higher revenue and earnings than iRadimed. TransMedics Group is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.41	$22.48M	$1.79	49.08
TransMedics Group	$605.49M	5.41	$190.29M	$3.89	24.36

iRadimed has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

92.3% of iRadimed shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 34.6% of iRadimed shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

iRadimed beats TransMedics Group on 10 of the 17 factors compared between the two stocks.

Get iRadimed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRMD vs. The Competition

Export

Metric	iRadimed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.12B	$6.02B	$7.37B	$12.85B
Dividend Yield	0.91%	1.75%	2.53%	11.08%
P/E Ratio	49.08	26.67	272.60	24.24
Price / Sales	13.41	45.38	618.96	99.81
Price / Cash	47.26	33.24	78.62	53.99
Price / Book	11.04	6.23	13.05	6.20
Net Income	$22.48M	$150.07M	$3.47B	$348.59M
7 Day Performance	1.04%	0.69%	2.09%	0.08%
1 Month Performance	-6.40%	8.91%	6.64%	3.88%
1 Year Performance	20.91%	8.07%	25.02%	16.98%

iRadimed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRMD iRadimed	3.3713 of 5 stars	$87.85 +1.3%	$120.00 +36.6%	+20.9%	$1.12B	$83.81M	49.08	110	Positive News
LIVN LivaNova	2.4671 of 5 stars	$79.95 -1.9%	$83.50 +4.4%	+40.9%	$4.40B	$1.47B	23.65	3,300	Positive News Analyst Upgrade
ITGR Integer	2.6564 of 5 stars	$125.20 +0.1%	$109.86 -12.3%	+13.2%	$4.26B	$1.85B	34.21	11,000	Positive News
IRTC iRhythm Technologies	3.9434 of 5 stars	$118.20 +1.1%	$179.93 +52.2%	-24.0%	$3.90B	$825.34M	N/A	2,400	Analyst Forecast
PLSE Pulse Biosciences	1.2705 of 5 stars	$47.29 +1.1%	$45.25 -4.3%	+195.7%	$3.27B	$350K	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRMD) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRadimed (IRMD) Competitors

IRMD vs. LIVN, ITGR, IRTC, PLSE, and TMDX

How does iRadimed compare to LivaNova?

Summary

How does iRadimed compare to Integer?

Summary

How does iRadimed compare to iRhythm Technologies?

Summary

How does iRadimed compare to Pulse Biosciences?

Summary

How does iRadimed compare to TransMedics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRadimed (IRMD) Competitors

IRMD vs. LIVN, ITGR, IRTC, PLSE, and TMDX

How does iRadimed compare to LivaNova?

Does the media refer more to LIVN or IRMD?

Do insiders and institutionals believe in LIVN or IRMD?

Do analysts prefer LIVN or IRMD?

Which has more volatility and risk, LIVN or IRMD?

Is LIVN or IRMD more profitable?

Which has better earnings & valuation, LIVN or IRMD?

Summary

How does iRadimed compare to Integer?

Do analysts prefer IRMD or ITGR?

Is IRMD or ITGR more profitable?

Which has more risk & volatility, IRMD or ITGR?

Do institutionals & insiders have more ownership in IRMD or ITGR?

Which has stronger earnings and valuation, IRMD or ITGR?

Does the media favor IRMD or ITGR?

Summary

How does iRadimed compare to iRhythm Technologies?

Which has more risk and volatility, IRMD or IRTC?

Does the media favor IRMD or IRTC?

Which has higher valuation & earnings, IRMD or IRTC?

Do analysts prefer IRMD or IRTC?

Is IRMD or IRTC more profitable?

Do institutionals and insiders believe in IRMD or IRTC?

Summary

How does iRadimed compare to Pulse Biosciences?

Which has more risk & volatility, IRMD or PLSE?

Is IRMD or PLSE more profitable?

Do institutionals & insiders believe in IRMD or PLSE?

Does the media refer more to IRMD or PLSE?

Do analysts prefer IRMD or PLSE?

Which has preferable earnings and valuation, IRMD or PLSE?

Summary

How does iRadimed compare to TransMedics Group?

Is IRMD or TMDX more profitable?

Do analysts prefer IRMD or TMDX?

Does the media prefer IRMD or TMDX?

Which has higher earnings & valuation, IRMD or TMDX?

Which has more volatility & risk, IRMD or TMDX?

Do insiders & institutionals believe in IRMD or TMDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools